Investors Pony Up $27M for Acetylon's HDAC6 Inhibitors
By Trista Morrison
Wednesday, June 29, 2011
With early stage venture funding hard to come by, Acetylon Pharmaceuticals Inc. has found an alternative way to fund its development of isoform-selective histone deacetylase (HDAC) inhibitors. The Boston-based biopharma has raised $27 million in Series B financing from a large contingent of private individuals.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.